Neumora Therapeutics (NMRA) Preferred Stock Liabilities (2022 - 2023)

Neumora Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $843.7 million for Q2 2023.

• In Q2 2023, Preferred Stock Liabilities changed N/A year-over-year to $843.7 million; the TTM figure through Jun 2023 stood at $843.7 million (changed N/A YoY), while the FY2022 annual figure was $843.7 million, changed N/A from the prior year.
• Preferred Stock Liabilities for Q2 2023 stood at $843.7 million, roughly flat from $843.7 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $843.7 million in Q4 2022, with the low at $817.1 million in Q3 2022.